Clinical Trials on Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer in Netherlands
Total 29 results
-
Leiden University Medical CenterThe Netherlands Cancer Institute; Borstkanker Onderzoek Groep; Comprehensive... and other collaboratorsSuspendedHER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer | Neoadjuvant Chemotherapy | Fasting Mimicking Diet | Pathological Complete Response | Objective Response RateNetherlands
-
The Netherlands Cancer InstituteAstraZeneca; Daiichi SankyoRecruiting
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
Novartis PharmaceuticalsCompletedEstrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA GeneUnited States, Netherlands, Spain, Germany, United Kingdom
-
The Netherlands Cancer InstituteCompletedBreast Cancer | HER2 PositiveNetherlands
-
Novartis PharmaceuticalsCompletedAdvanced HER2-positive Breast Cancer or Gastric CancerTaiwan, Netherlands, Italy, United States, Belgium, United Kingdom, Korea, Republic of, France, Spain
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive Breast CancerUnited States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
-
The Netherlands Cancer InstituteRoche Pharma AG; Borstkanker Onderzoek GroepActive, not recruitingBreast Cancer | HER2 PositiveNetherlands
-
Amsterdam UMC, location VUmcNovartis; Borstkanker Onderzoek GroepUnknownMetastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastNetherlands
-
Jules Bordet InstituteRoche Pharma AGActive, not recruitingHER-2 Positive Breast CancerBelgium, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER-2 Positive Breast CancerBelgium, Netherlands, Australia, Italy, United States
-
Eli Lilly and CompanyCompletedBreast Cancer | Early-Stage Breast Carcinoma | Hormone Receptor Positive TumorUnited States, Canada, Korea, Republic of, Italy, Austria, Belgium, Germany, Netherlands, Spain, Taiwan
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
AstraZenecaCompletedAdvanced Ovarian Cancer | Paclitaxel | Carboplatin | Triple Negative Metastatic Breast CancerBelgium, Netherlands, United Kingdom
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
The Netherlands Cancer InstituteCompletedBreast Cancer | Ovarian Cancer | Advanced CancerNetherlands
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
ExelixisRecruitingCervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid TumorsUnited States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
-
MacroGenicsCompletedHER-2 Positive Breast Cancer | Metastatic NeoplasmUnited States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
-
Novartis PharmaceuticalsCompletedMelanoma | Triple Negative Breast Cancer | Anaplastic Thyroid Cancer | Other Solid Tumors | Non-small Sell Lung Cancer (NSCLC)United States, Italy, Spain, Hungary, Taiwan, Germany, Netherlands, France, Norway, Poland, Thailand, Lebanon, Turkey, Canada
-
ExelixisActive, not recruitingA Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm MalignantUnited States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
Novartis PharmaceuticalsActive, not recruitingMelanoma | Pancreatic Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Cancer | Esophageal Squamous Cell Cancer | BRAF Mutant Colorectal Cancer | Cervical Squamous Cell Cancer | Lung Squamous Cell CancerCanada, Italy, Spain, Germany, Netherlands, United States, France
-
Novartis PharmaceuticalsTerminatedMelanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
-
Radboud University Medical CenterUnknownOvarian Cancer | Endometrial Cancer | Advanced/Recurrent Breast CancerNetherlands
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerCanada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
-
ExelixisActive, not recruitingRenal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditionsUnited States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
Seagen Inc.RecruitingMelanoma | Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Ovarian Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Neoplasms | Esophageal Squamous Cell CarcinomaUnited States, Spain, Italy, Canada, United Kingdom, France, Belgium, Germany, Netherlands